ANGELA KLINE: Open Payments
NPI 1083788483 · VANCOUVER, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,532 in 122 payments from 16 companies in 2025. Trend: 2023 $2,341 · 2024 $2,562 · 2025 $2,532
Food & beverage: $2,532
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $346 |
| E.R. Squibb & Sons, L.L.C. | 15 | $338 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $306 |
| Lundbeck LLC | 13 | $241 |
| ABBVIE INC. | 13 | $233 |
| Vanda Pharmaceuticals Inc. | 11 | $231 |
| Neurocrine BioSciences, Inc. | 5 | $188 |
| HARMONY BIOSCIENCES LLC | 10 | $186 |
| Collegium Pharmaceutical, Inc. | 6 | $182 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
Products named: REXULTI, COBENFY, CAPLYTA, VRAYLAR, INGREZZA, WAKIX, Jornay PM, FANAPT.
Industry payments across WA — which companies pay providers there.
